ACTON, Mass.--(BUSINESS WIRE)--Cognoptix, an emerging medical device company that is developing the SAPPHIRE II eye test designed to identify early-stage Alzheimer’s Disease (AD) patients via a beta-amyloid (A-beta) signature in their eyes, announced today that it has appointed Barry D. Greenberg, Ph.D., to its Clinical Advisory Board. Dr. Greenberg is Director of Neuroscience Drug Discovery & Development at University Health Network (UHN), Toronto; and, Director of Strategy, Toronto Dementia Research Alliance.
Help employers find you! Check out all the jobs and post your resume.
